Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter - Test2 - elhamkhani - TriplyDB

Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter

Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter

http://www.wikidata.org/entity/Q26829749

about

Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs σ Receptor Effects of N-Substituted Benztropine Analogs: Implications for Antagonism of Cocaine Self-Administration Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue.2-Substituted 3β-Aryltropane Cocaine Analogs Produce Atypical Effects without Inducing Inward-Facing Dopamine Transporter Conformations.Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.Binding Mode Selection Determines the Action of Ecstasy Homologs at Monoamine Transporters A role for sigma receptors in stimulant self-administration and addiction.Rigid Adenine Nucleoside Derivatives as Novel Modulators of the Human Sodium Symporters for Dopamine and Norepinephrine.Cocaine Antagonists; Studies on Cocaine Self-Administration.Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters.Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters.DAT Conformation Does Not Predict the Ability of Atypical Dopamine Uptake Inhibitors to Substitute for Cocaine.Targeting species-specific trace amine-associated receptor 1 ligands: to date perspective of the rational drug design process.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.Neurotoxicology of Synthetic Cathinone Analogs.Metabolic and Cardiovascular Benefits and Risks of EMD386088-A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor.Decoding the Structure of Abuse Potential for New Psychoactive Substances: Structure-Activity Relationships for Abuse-Related Effects of 4-Substituted Methcathinone Analogs.Structure-Activity Relationships of Synthetic Cathinones.CTDP-32476: A Promising Agonist Therapy for Treatment of Cocaine Addiction.Overview of Monoamine Transporters.Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons.Behavioral economic analysis of the effects of N-substituted benztropine analogs on cocaine self-administration in rats.Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders.The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic.Molecular dynamics of conformation-specific dopamine transporter-inhibitor complexes.Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats.Gestational Exposure to the Synthetic Cathinone Methylenedioxypyrovalerone Results in Reduced Maternal Care and Behavioral Alterations in Mouse Pups.Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects.A Role for Sigma Receptors in Stimulant Self-Administration and Addiction.Dopamine Transporter Dynamics of -Substituted Benztropine Analogs with Atypical Behavioral Effects

P2860

Q26752602-2CC31166-4353-445E-960B-CC513FAD99F7 Q33566201-D0C0209F-C409-45DF-BB89-C2AC193A2C11 Q33754479-26F11C74-BC62-4CDE-97E8-AB8F1CC1E8D6 Q34467830-E848420F-A9B9-475D-BB80-6DC680DD1197 Q34493739-A146B4E7-3CAF-4ED9-AA30-4F9908FCD162 Q34509115-1F3F85A8-761A-415A-AC05-54628C0B658E Q34673305-0A2996E9-3D3D-46A6-95C1-BEBF46EDF355 Q36432395-FA46499A-7BDC-4F86-987F-BD87BDAD36D8 Q36655919-56B2B6F5-880F-4BEF-8533-2C90435F163B Q36733500-6AC5009E-ABDE-47E1-9D64-AE3D39D3873F Q37073018-25E4AAAF-7046-4A12-AE3C-31EA598B9099 Q37161370-A594E07F-C76E-4A26-AA53-97CFD0499CD4 Q37168973-35EB0DE3-8125-43DC-85B8-19663274A482 Q37217135-663FD609-377D-4900-A682-4B49D6565636 Q38644990-BD224C62-F0A2-4808-AEAC-3B449C591393 Q38926644-9CA14AD3-DC3B-4755-9337-1DC939EFCD98 Q38983638-E8262EB4-1B64-4CDF-AC9A-36631CF89B87 Q42323374-63C86A2E-1647-42FA-AF80-BC99AE57C60D Q45044131-E72D7BFE-92F8-4DEF-AB99-CF4F6BF4F2A2 Q45046796-80A9B1C6-A2DF-40ED-AF5C-C06F366AAD73 Q46043227-4D736D7C-56E6-44C3-852C-9C74BAC7E80D Q47271566-F8CE552C-6CC1-4C16-8A7E-86138011FF64 Q47729702-F050760B-7A12-44AC-BBC4-BC4B9CC5820A Q47825128-BCD65A6E-BD21-4F1F-A0FD-5BF926BB6F88 Q47950931-61B20CE2-5996-4E78-A85F-3DB51C1666A9 Q48141734-DFF5BC98-4181-4F0F-A639-C787670ADB37 Q48156370-B6386363-038C-4EA7-BFED-9F4DCF7C154B Q48184197-E458D6B8-9E52-40C6-AB28-247525D279FC Q50023810-A883B354-306E-4C56-86AE-C3146F02E8D4 Q50074132-4744AD91-2806-423E-9340-763CD6DB7A96 Q51009516-9091D52A-58D7-46F7-9146-BBD06A396B33 Q51175465-C882DC6B-E84C-4AFF-AE7E-896916637145 Q58777932-073D55FF-B363-49BF-9306-7F31CCA4C7AA

P2860

Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter

http://www.wikidata.org/entity/Q26829749

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Behavioral, biological, and ch ...... eting the dopamine transporter

@ast

Behavioral, biological, and ch ...... eting the dopamine transporter

@en

Behavioral, biological, and ch ...... eting the dopamine transporter

@nl

type

label

Behavioral, biological, and ch ...... eting the dopamine transporter

@ast

Behavioral, biological, and ch ...... eting the dopamine transporter

@en

Behavioral, biological, and ch ...... eting the dopamine transporter

@nl

prefLabel

Behavioral, biological, and ch ...... eting the dopamine transporter

@ast

Behavioral, biological, and ch ...... eting the dopamine transporter

@en

Behavioral, biological, and ch ...... eting the dopamine transporter

@nl

P1433

Q26829749-AF8724DC-2B2A-4455-87A4-6BB21184AA27

P1476

Q26829749-8300A020-F11C-4F53-AA45-591213E727E9

P2093

Q26829749-24F91F56-C8E7-4824-8293-2B9990C6C7B5

Q26829749-6656068C-1160-4ED2-AA6C-4B688CBD8AF3

Q26829749-718E8BE2-054F-4175-8594-8E3B8ADC1C3E

Q26829749-85C3E170-0A8B-4760-9519-8EB0A8CDECCE

Q26829749-A03327F4-7B77-42D2-B638-256CFD854F6D

Q26829749-DCB2451F-2473-4B79-A71B-8AFE4E24E2B8

Q26829749-E048437C-AD10-491C-AE15-D40C84F92712

P2860

Q26829749-039F90EE-51DD-4474-9714-C1DC14ABE6D9

Q26829749-04D45929-947B-43D7-B719-1EDCE052F83B

Q26829749-07B26DA2-2CBF-4E37-A99B-7D45C1153C35

Q26829749-08063077-B3E3-4F32-AB3F-1FF4671EAF19

Q26829749-0BB66317-9FAE-408F-BD13-61D3FB176661

Q26829749-0D09BE2B-EFB9-45ED-9ED2-E82E0C072E94

Q26829749-103185B2-97F7-4185-8E05-BFE924AF9C96

Q26829749-17BD4DCB-AF76-42D7-B2F0-CB5111D13A91

Q26829749-1C837D04-347D-4665-8D45-63126CEB574D

Q26829749-1CA37B6C-BA6D-4177-8094-094577B06023

P304

Q26829749-5EF1EF2B-FD73-49C0-BEAD-40934BDE21F6

P31

Q26829749-BCFFFEAB-D082-442C-BA5C-15C8F6B858AD

P3181

Q26829749-9B0DD57F-AC3F-470E-8DFF-4090F66550D0

P356

Q26829749-DFA196D7-74AE-4BC0-8646-113FD72AE704

P407

Q26829749-618FEDC5-B253-435D-9C77-4D9BA063FCFD

P478

Q26829749-AE2AF3FC-E370-4AB5-8283-AEB50E575287

P50

Q26829749-1258D38A-CD43-4C0D-A8C2-B349C79A7641

Q26829749-3C90B7E4-7BC5-4B52-99F7-7613A9DA76DB

P577

Q26829749-E5042783-DC71-481C-A88C-064D3351A4C7

P5875

Q26829749-63FF1FFD-FC15-4B3F-B95C-31A971C3844D

P698

Q26829749-106783D3-5D64-401C-8B85-0F51B01F4F68

P921

Q26829749-271dafc0-d9c5-44c9-93bc-31659b3a4239

P932

Q26829749-11F0EA7F-0BCA-4C73-983D-D8530F556D13

P3181

P356

J.DRUGALCDEP.2014.12.005

P1433

Drug and Alcohol Dependence

P1476

Behavioral, biological, and ch ...... eting the dopamine transporter

@en

P2093

Bruce E Blough

http://www.w3.org/2001/XMLSchema#string

John S Partilla

http://www.w3.org/2001/XMLSchema#string

Kymry T Jones

http://www.w3.org/2001/XMLSchema#string

Maarten E A Reith

http://www.w3.org/2001/XMLSchema#string

Michael H Baumann

http://www.w3.org/2001/XMLSchema#string

Richard B Rothman

http://www.w3.org/2001/XMLSchema#string

Weimin C Hong

http://www.w3.org/2001/XMLSchema#string

P2860

Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT

LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake

X-ray structure of dopamine transporter elucidates antidepressant mechanism

R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse

Targeting sigma receptors: novel medication development for drug abuse and addiction

How addictive drugs disrupt presynaptic dopamine neurotransmission

In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat

Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter

Modafinil for the treatment of cocaine dependence

Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures

P304

1-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2471382

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.DRUGALCDEP.2014.12.005

http://www.w3.org/2001/XMLSchema#string

P407

P478

147

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan L. Katz

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270291308

http://www.w3.org/2001/XMLSchema#string

P698

25548026

http://www.w3.org/2001/XMLSchema#string

P921

P932

4297708

http://www.w3.org/2001/XMLSchema#string